{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:27:58Z","timestamp":1787027278440,"version":"build-2736575974"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>High prices have limited access to targeted anticancer drugs in China. In 2017, 18 such drugs were added to the National Reimbursement Drug List (NRDL) through national price negotiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Monthly hospital procurement data (2015\u20132019) from 887 public hospitals across 30 provinces were analyzed. Drug utilization was measured by expenditures and defined daily doses (DDDs). A difference-in-differences (DID) model and interrupted time series (ITS) analysis were employed to estimate policy effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Following policy implementation, total DDDs of negotiated drugs rose 4.03-fold and expenditures 3.07-fold, both exceeding cancer incidence growth. DID analysis confirmed significant increases for Western medicines (+479,100 DDDs;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001). ITS showed sustained upward trends, especially for Trastuzumab, Bevacizumab, and Abiraterone, while traditional Chinese medicines declined. Bevacizumab demonstrated improved affordability, with higher DDDs but lower expenditures.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The NRDL negotiation substantially improved access to targeted anticancer therapies in public hospitals while containing cost growth. These findings highlight the effectiveness of centralized price negotiation in expanding coverage and equity of high-cost cancer treatments in resource-constrained settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2025.1662346","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T06:32:44Z","timestamp":1765521164000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Effect of the national reimbursement drug list negotiation policy on utilization of negotiated anticancer drugs in Chinese public hospital: a quasi-natural experiment"],"prefix":"10.3389","volume":"13","author":[{"given":"Gang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hezheng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qunhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghan","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1001\/jamaoncol.2021.6987","article-title":"Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the global burden of disease study 2019","volume":"8","author":"Kocarnik","year":"2022","journal-title":"JAMA Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.31557\/APJCP.2021.22.12.3755","article-title":"Economic burden of Cancer treatment in a region in South India: A cross sectional analytical study","volume":"22","author":"Maurya","year":"2021","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.3390\/curroncol29040223","article-title":"The economic burden of Cancer in Canada from a societal perspective","volume":"29","author":"Garaszczuk","year":"2022","journal-title":"Curr Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.20892\/j.issn.2095-3941.2022.0231","article-title":"Current cancer burden in China: epidemiology, etiology, and prevention","volume":"19","author":"Cao","year":"2022","journal-title":"Cancer Biol Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1200\/JCO.2011.40.3824","article-title":"The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs","volume":"30","author":"Niraula","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref6","volume-title":"Drug utilization research (methods and applications)","year":"2016"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1200\/JCO.2005.01.016","article-title":"What is targeted therapy?","volume":"23","author":"Sledge","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nrclinonc.2017.31","article-title":"The high price of anticancer drugs: origins, implications, barriers, solutions","volume":"14","author":"Prasad","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S1470-2045(21)00463-0","article-title":"Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey","volume":"22","author":"Fundytus","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/CM9.0000000000001474","article-title":"Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020","volume":"134","author":"Cao","year":"2021","journal-title":"Chin Med J"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"71548","DOI":"10.18632\/oncotarget.17742","article-title":"A global comparison of the cost of patented cancer drugs in relation to global differences in wealth","volume":"8","author":"Goldstein","year":"2017","journal-title":"Oncotarget"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"578","DOI":"10.3390\/ijerph19084578","article-title":"Impacts of national drug price negotiation on expenditure, volume, and availability of targeted anti-cancer drugs in China: an interrupted time series analysis","volume":"19","author":"Sun","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"ref13","year":""},{"key":"ref14","year":""},{"key":"ref15","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1017\/S1744133122000068","article-title":"Pricing strategies, executive committee power and negotiation leverage in New Zealand's containment of public spending on pharmaceuticals","volume":"17","author":"Main","year":"2022","journal-title":"Health Econ Policy Law"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/imj.13350","article-title":"Is it all about price? Why requests for government subsidy of anticancer drugs were rejected in Australia","volume":"47","author":"Karikios","year":"2017","journal-title":"Intern Med J"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1136\/bmj.39136.464421.BE","article-title":"The pharmaceutical price regulation scheme","volume":"334","author":"Collier","year":"2007","journal-title":"BMJ"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.healthpol.2013.12.008","article-title":"Early benefit assessment of new drugs in Germany - results from 2011 to 2012","volume":"116","author":"H\u00f6rn","year":"2014","journal-title":"Health Policy"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.34172\/ijhpm.2021.47","article-title":"Trends of negotiated targeted anticancer medicines use in China: an interrupted time series analysis","volume":"11","author":"Huang","year":"2021","journal-title":"Int J Health Policy Manag"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"714127","DOI":"10.3389\/fpubh.2021.714127","article-title":"Impact of the National Health Insurance Coverage Policy on the utilisation and accessibility of innovative anti-cancer medicines in China: an interrupted time-series study","volume":"9","author":"Fang","year":"2021","journal-title":"Front Public Health"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1053\/j.seminoncol.2021.03.001","article-title":"Can locally developed me-too drugs aid price negotiation? An example of cancer therapies from China","volume":"48","author":"Luo","year":"2021","journal-title":"Semin Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"958","DOI":"10.3969\/j.issn.1674-9081.2020.00.018","article-title":"Investigation on the clinical application of 17 national medical insurance negotiation anticancer drugs in Peking union medical college hospital","volume":"12","author":"Sun","year":"2020","journal-title":"Med J Peking Union Med Coll Hosp"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.7664\/CHE20181007","article-title":"Evaluation of targeted anticancer agents incorporated into medical insurance policy: taking a tertiary oncology institution in Beijing as an example","volume":"37","author":"Chen","year":"2018","journal-title":"Chin Health Econ"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3969\/j.issn.1001-568X.2020.09.003","article-title":"Investigation on the effect of 17 national negotiation anti-cancer drugs included in the medical insurance of Tianjin on cancer patients","volume":"34","author":"Xu","year":"2020","journal-title":"Chin Prim Health Care"},{"key":"ref25","year":""},{"key":"ref26","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1186\/s12913-024-11285-5","article-title":"Access to essential and innovative anti-cancer medicines: a longitudinal study in Nanjing, China","volume":"24","author":"Cao","year":"","journal-title":"BMC Health Serv Res"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"11016","DOI":"10.7189\/jogh.12.11016","article-title":"Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: a controlled interrupted time series study","volume":"12","author":"Cai","year":"","journal-title":"J Glob Health"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.2147\/RMHP.S473846","article-title":"New evidence of the impact of the National Drug Price Negotiation Policy on the availability, utilization, and cost of anticancer medicines in China: an interrupted time series study","volume":"17","author":"Gao","year":"2024","journal-title":"Risk Manag Healthc Policy"},{"key":"ref29","year":"2019"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1177\/0962280218814570","article-title":"Now trending: coping with non-parallel trends in difference-in-differences analysis","volume":"28","author":"Ryan","year":"2019","journal-title":"Stat Med Res"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1016\/j.jeconom.2023.03.008","article-title":"What\u2019s trending in difference-in-differences? A synthesis of the recent econometrics literature","volume":"235","author":"Roth","year":"2023","journal-title":"J Econom"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"h2750","DOI":"10.1136\/bmj.h2750","article-title":"Regression based quasi-experimental approach when randomisation is not an option: interrupted time series analysis","volume":"350","author":"Kontopantelis","year":"2015","journal-title":"BMJ"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10742-016-0146-8","article-title":"Estimating causal effects: considering three alternatives to difference-in-differences estimation","volume":"16","author":"O'Neill","year":"2016","journal-title":"Health Serv Outcomes Res Methodol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/s0166-4328(01)00297-2","article-title":"Controlling the false discovery rate in behavior genetics research","volume":"125","author":"Benjamini","year":"2001","journal-title":"Behav Brain Res"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12874-019-0754-4","article-title":"Methods to adjust for multiple comparisons in the analysis and sample size calculation of randomised controlled trials with multiple primary outcomes","volume":"19","author":"Vickerstaff","year":"2019","journal-title":"BMC Med Res Methodol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s10592-005-9056-y","article-title":"Beyond bonferroni: less conservative analyses for conservation genetics","volume":"7","author":"Narum","year":"2006","journal-title":"Conserv Genet"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.anbehav.2019.07.001","article-title":"Multiple testing: correcting for alpha error inflation with false discovery rate (FDR) or family-wise error rate?","volume":"155","author":"Voelkl","year":"2019","journal-title":"Anim Behav"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1021\/acs.analchem.2c03719","article-title":"Costs and benefits of popular P-value correction methods in three models of quantitative omic experiments","volume":"95","author":"Shuken","year":"2023","journal-title":"Anal Chem"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3760\/cma.j.issn.0253-3766.2019.01.005","article-title":"Report of cancer epidemiology in China, 2015","volume":"41","author":"Zheng","year":"2019","journal-title":"Chin J Oncol."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jncc.2022.02.002","article-title":"Cancer incidence and mortality in China, 2016","volume":"45","author":"Zheng","year":"2023","journal-title":"Chin J Oncol"},{"key":"ref41","year":""},{"key":"ref42","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40880-019-0368-6","article-title":"Current cancer situation in China: good or bad news from the 2018 global Cancer statistics?","volume":"39","author":"Feng","year":"2019","journal-title":"Cancer Commun (Lond)"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.vhri.2019.04.006","article-title":"The impact of Price negotiations on public procurement prices and access to 8 innovative Cancer medicines in a middle-income country: the case of Mexico","volume":"20","author":"Moye-Holz","year":"2019","journal-title":"Value Health Reg Issues"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1377\/hlthaff.2019.01122","article-title":"Lessons from the impact of price regulation on the pricing of anticancer drugs in Germany","volume":"39","author":"Lauenroth","year":"2020","journal-title":"Health Aff Millwood"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","article-title":"Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group","volume":"23","author":"Marty","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1200\/JCO.2003.02.018","article-title":"Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm","volume":"21","author":"Burstein","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00280-007-0497-5","article-title":"A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan breast Cancer research network (JBCRN) 00 trial","volume":"61","author":"Yamamoto","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1142\/S0192415X18500507","article-title":"Application of traditional Chinese medicines as personalized therapy in human cancers","volume":"46","author":"Wang","year":"2018","journal-title":"Am J Chin Med"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"2417418","DOI":"10.1155\/2019\/2417418","article-title":"Ginsenoside Rg3 (Shenyi capsule) combined with chemotherapy for digestive system cancer in China: a meta-analysis and systematic review","volume":"2019","author":"Pan","year":"","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1200\/JCO.23.01891","article-title":"Phase III, randomized study of Atezolizumab plus bevacizumab and chemotherapy in patients with EGFR- or ALK-mutated non-small-cell lung Cancer (ATTLAS, KCSG-LU19-04)","volume":"42","author":"Park","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1158\/1078-0432.CCR-24-0006","article-title":"Toripalimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma: A prospective, multicenter, single-arm","volume":"30","author":"Chen","year":"2024","journal-title":"Phase II Trial Clin Cancer Res"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1089\/jpm.2020.0396","article-title":"Early palliative home care versus Hospital Care for Patients with hematologic malignancies: A cost-effectiveness study","volume":"24","author":"Cartoni","year":"2021","journal-title":"J Palliat Med"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1186\/s12889-024-18820-3","article-title":"The usage and costs of national drug price-negotiated anticancer medicines in a first-tier city in Northeast China: a study based on health insurance data","volume":"24","author":"Li","year":"2024","journal-title":"BMC Public Health"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"4069","DOI":"10.7189\/jogh.15.04069","article-title":"Evaluation of changes in price, volume and expenditure of PD-1 drugs following the government reimbursement negotiation in China: a multiple-treatment period interrupted time series analysis","volume":"15","author":"Yi","year":"2025","journal-title":"J Glob Health"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1186\/s12889-022-14525-7","article-title":"The impacts of the National Medication Price-Negotiated Policy on the financial burden of cancer patients in Shandong province, China: an interrupted time series analysis","volume":"22","author":"Ding","year":"2022","journal-title":"BMC Public Health"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12939-025-02390-w","article-title":"Impacts of national reimbursement drug price negotiation on drug accessibility, utilization, and cost in China: a systematic review","volume":"24","author":"Zhu","year":"2025","journal-title":"Int J Equity Health"},{"key":"ref58","first-page":"e069645","article-title":"Trends in antineoplastic drug use, cost and prescribing patterns among patients with lung cancer in nine major cities of China, 2016-2020: a retrospective observational study based on inpatient and outpatient hospital data","author":"Shang","year":"2023"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1177\/00469580231170729","article-title":"Promoting access to innovative anticancer medicines: a review of drug price and national reimbursement negotiation in China","volume":"60","author":"Xia","year":"2023","journal-title":"Inquiry"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.3389\/fpubh.2022.921093","article-title":"Impact of the national reimbursement drug list negotiation policy on accessibility of anticancer drugs in China: an interrupted time series study","volume":"10","author":"Zhu","year":"","journal-title":"Front Public Health"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1177\/1073110520958885","article-title":"An international review of health technology assessment approaches to prescription drugs and their ethical principles","volume":"48","author":"Rand","year":"2020","journal-title":"J Law Med Ethics"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.3390\/curroncol29030127","article-title":"Health technology assessment process for oncology drugs: impact of CADTH changes on public payer reimbursement recommendations","volume":"29","author":"Binder","year":"2022","journal-title":"Curr Oncol"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"e1004332","DOI":"10.1371\/journal.pmed.1004332","article-title":"Price negotiation and pricing of anticancer drugs in China: an observational study","volume":"21","author":"Zhou","year":"2024","journal-title":"PLoS Med"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1177\/26320843211061306","article-title":"Measuring the sensitivity of difference-in-difference estimates to the parallel trends assumption","volume":"2","author":"Gibson","year":"2021","journal-title":"Res Methods Med Health Sci"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1662346\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T06:32:50Z","timestamp":1765521170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1662346\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":64,"alternative-id":["10.3389\/fpubh.2025.1662346"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1662346","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"article-number":"1662346"}}